GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Guided Therapeutics GTHP · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.11

+10.00%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Guided Therapeutics — daily GTHP Delayed
Market value
$6.3m
Last close × shares
Volume
136.1k
Shares, 9 Nov 2026

About Guided Therapeutics

From its filings with the US Securities and Exchange Commission

SEC filings

Guided Therapeutics is based in Peachtree Corners, Georgia and is incorporated in Delaware. Its shares trade on OTC under the ticker GTHP. The SEC classifies its business as electromedical & electrotherapeutic apparatus. In the fiscal year to 31 December 2025, it reported revenue of $767,000 and a net loss of $3.2m. At that date it held total assets of $1.3m and shareholders' equity of −$6.0m.

In its own words

We are a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. Our primary focus is the sales and marketing of our LuViva® Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light.

LuViva is designed to provide a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva is designed to improve patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care. We focus on two primary applications for LuViva: first, as a cancer screening tool in the developing world, where infrastructure to support traditional cancer-screening methods is limited or non-existent, and second, as a triage following traditional screening in the developed world, where a high number of false positive results cause a high rate of unnecessary and ultimately costly follow-up tests.

Quoted from its 10-K, filed 31 Mar 2026. Read the filing on SEC.gov ↗

More about Guided Therapeutics →

How it makes its money

Revenue, year to 31 Dec 2019

  • Devices $17,000 · 47.2%
  • Other $15,000 · 41.7%
  • Disposables $2,000 · 5.6%
  • Warranty $2,000 · 5.6%

Latest on Guided Therapeutics

Our reporting

We have not reported on Guided Therapeutics yet.

Next results

11 Nov 2026

Due on 11 Nov 2026.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Guided Therapeutics's ticker?

Guided Therapeutics trades as GTHP on its US listing, under ISIN US40171F5017.

What was Guided Therapeutics's last closing price?

0.11 on 9 Nov 2026. The figure is in USD and is never converted.

When does Guided Therapeutics next report results?

Results are expected on 11 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.